Tesamorelin Ipamorelin (peptidedosingprotocols.com)

How it works

The tesamorelin + ipamorelin blend pairs two compounds that raise growth hormone (GH) through different doors. Tesamorelin is a synthetic GHRH analog: it copies growth hormone-releasing hormone and tells the pituitary gland to make more GH. Ipamorelin is a ghrelin mimetic (a growth hormone secretagogue): it acts on a separate receptor to add to the same GH pulse. This combination is based on the idea that pairing a GHRH analog with a ghrelin-mimetic GH secretagogue can produce larger, amplified GH pulses than either agent alone, as shown in human secretagogue studies. The blend applies that same two-pathway logic.

Tesamorelin operates through the GHRH-receptor pathway, which has been FDA-studied and is known to drive visceral fat reduction. On the other hand, Ipamorelin works through the GHS-R1a (ghrelin) pathway, which is selective for GH and has little effect on cortisol or prolactin in animal studies. However, it is important to note that the main limitation is that synergy has been shown for GHRH combined with secretagogue classes in general, not specifically for this exact blend in a human trial. [Source: Peptide Dosing Protocols]

Plain language: The combination of tesamorelin and ipamorelin works by stimulating growth hormone release through different pathways, enhancing the overall effect.

Who should avoid it

Individuals who are pregnant should avoid this blend, as tesamorelin is contraindicated in pregnancy. Additionally, those with glucose intolerance or a higher risk of type 2 diabetes should exercise caution, as GH elevation can lower insulin sensitivity. There are no specific groups or conditions mentioned beyond these cautions. [Source: Peptide Dosing Protocols]

Plain language: Pregnant individuals and those with glucose intolerance should avoid this blend.